

S 252

Medicare Drug Savings Act of 2017

Congress: 115 (2017–2019, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Feb 1, 2017

Current Status: Read twice and referred to the Committee on Finance.

Latest Action: Read twice and referred to the Committee on Finance. (Feb 1, 2017)

Official Text: <https://www.congress.gov/bill/115th-congress/senate-bill/252>

Sponsor

Name: Sen. Nelson, Bill [D-FL]

Party: Democratic • **State:** FL • **Chamber:** Senate

Cosponsors (15 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Baldwin, Tammy [D-WI]	D · WI		Feb 1, 2017
Sen. Blumenthal, Richard [D-CT]	D · CT		Feb 1, 2017
Sen. Brown, Sherrod [D-OH]	D · OH		Feb 1, 2017
Sen. Durbin, Richard J. [D-IL]	D · IL		Feb 1, 2017
Sen. Franken, Al [D-MN]	D · MN		Feb 1, 2017
Sen. Hirono, Mazie K. [D-HI]	D · HI		Feb 1, 2017
Sen. King, Angus S., Jr. [I-ME]	I · ME		Feb 1, 2017
Sen. Klobuchar, Amy [D-MN]	D · MN		Feb 1, 2017
Sen. Leahy, Patrick J. [D-VT]	D · VT		Feb 1, 2017
Sen. Reed, Jack [D-RI]	D · RI		Feb 1, 2017
Sen. Sanders, Bernard [I-VT]	I · VT		Feb 1, 2017
Sen. Stabenow, Debbie [D-MI]	D · MI		Feb 1, 2017
Sen. Udall, Tom [D-NM]	D · NM		Feb 1, 2017
Sen. Whitehouse, Sheldon [D-RI]	D · RI		Feb 1, 2017
Sen. Shaheen, Jeanne [D-NH]	D · NH		Mar 7, 2017

Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Feb 1, 2017

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
115 S 3411	Related bill	Sep 5, 2018: Read twice and referred to the Committee on Finance.
115 HR 4138	Related bill	Oct 27, 2017: Referred to the Subcommittee on Health.
115 S 1511	Related bill	Jun 29, 2017: Read twice and referred to the Committee on Finance.
115 HR 1776	Related bill	Apr 5, 2017: Referred to the Subcommittee on Health.
115 S 771	Related bill	Mar 29, 2017: Read twice and referred to the Committee on Finance.

Summary (as of Feb 1, 2017)

Medicare Drug Savings Act of 2017

This bill requires drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services (CMS) for prescription drugs dispensed to eligible low-income individuals under the Medicare prescription drug benefit or a Medicare Advantage (MA) prescription drug plan (PDP).

Subject to civil monetary penalties, a Medicare or MA PDP sponsor must report, both to drug manufacturers and to the CMS, specified information related to the determination and payment of such rebates.

Actions Timeline

- **Feb 1, 2017:** Introduced in Senate
- **Feb 1, 2017:** Read twice and referred to the Committee on Finance.